Search Results
Sep 03, 2026, 10:00 ET SPYNE ANNOUNCES CDK INTEGRATION THROUGH THE FORTELLIS MARKETPLACE WITH VINI AI
Sept. 3, 2026 /PRNewswire/ -- Spyne, an AI-powered retail technology company for the automotive industry, today announced its integration with CDK to publish on The Fortellis Marketplace. This integration offers dealers, developers, and OEMs the ability to quickly create new solutions designed
More news about: Spyne
Sep 01, 2026, 07:15 ET Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
preclinical data demonstrating the safety and anti-tumor activity of paxalisib in HR+/HER2- breast cancer, including evidence that paxalisib resensitized CDK4/6 inhibitor-resistant tumors to standard-of-care therapy. Based on these findings, the Company is moving rapidly to expand its ongoing TNBC clinical
More news about: Kazia Therapeutics Limited
Aug 13, 2026, 08:05 ET Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
endocrine therapy remains a cornerstone of metastatic ER+/HER2- breast cancer treatment, up to 50% of patients treated with endocrine therapy and a CDK4/6 inhibitor acquire estrogen receptor 1 gene (ESR1) mutations, resulting in endocrine resistance and poor prognosis. Treatment options in second-line
More news about: Rigel Pharmaceuticals, Inc.
Aug 11, 2026, 20:45 ET New Drug Application for LAE002 (afuresertib) Accepted by China's National Medical Products Administration
cancer (LA/mBC) with PIK3CA/AKT1/PTEN alterations, following recurrence or progression on or after endocrine therapy(-ies) (with or without a CDK4/6 inhibitor). The NDA is supported by positive results from the Phase III Clinical Trial (AFFIRM-205) conducted in the aforementioned patient
More news about: Laekna
Aug 07, 2026, 08:45 ET Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
compounds generated during the synthesis of (Z)-endoxifen, alongside (Z)-endoxifen in a broad panel of laboratory assays, as well as in combination with the CDK4/6 inhibitor abemaciclib.The publication reported anti-estrogenic and anti-cancer activity across multiple ER-positive (ER+)
More news about: Atossa Therapeutics Inc
Aug 06, 2026, 15:00 ET Insignia Group Launches ACE, Accessory Commerce Infrastructure for the Automotive Industry
within OEM programs and digital retail ecosystems across the industry, including partners such as Kia, Volkswagen, Jaguar Land Rover, Cox Automotive, CDK Global, and DealerOn.Organizations that deploy ACE are intended to see accessory revenue captured at the point where buying decisions are made,
More news about: Insignia Group, LLC
Aug 04, 2026, 16:01 ET Rigel Reports Second Quarter 2026 Financial Results
endocrine therapy remains a cornerstone of metastatic ER+/HER2- breast cancer treatment, up to 50% of patients treated with endocrine therapy and a CDK4/6 inhibitor acquire estrogen receptor 1 gene (ESR1) mutations, resulting in endocrine resistance and poor prognosis. Treatment options in second-line
More news about: Rigel Pharmaceuticals, Inc.
Jul 30, 2026, 09:00 ET Resilience Claims Data Shows Human Error Drove Majority of Cyber Losses in First Half of 2026
Resilience data shows they do not always generate the same level of insured financial loss as major third-party breaches like Change Healthcare and CDK in previous years.As AI continues to increase the sophistication and scale of familiar attack methods, Resilience recommends organizations
More news about: Resilience
Jul 30, 2026, 08:19 ET Lokam.ai Accelerates U.S. Expansion with New Sales Director, Growing Dealership Roster, and Industry-First QoreAI Partnership
re-engagement outcomes, writes back into the platform for every other connected tool to use. The combined solution is compatible with Dealertrack, DealerVault, CDK, and Authenticom.Customers Are Seeing the Results in Real TimeScott Falcone, Owner of World Kia Joliet and World Hyundai Matteson,
More news about: Lokam.ai
Jul 28, 2026, 08:30 ET Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer
cell-cycle progression, migration, invasion, estrogen receptor transcriptional activity, gene-expression changes and activity in combination with the CDK4/6 inhibitor abemaciclib.Several compounds demonstrated potent anti-estrogenic effects, and affected multiple anti-cancer processes including
More news about: Atossa Therapeutics Inc
Jul 15, 2026, 10:31 ET Soft Tissue Sarcoma Market Set for Significant Growth at a CAGR of 7.9% During the Forecast Period (2026-2036), Driven by Novel Therapies and Expanding Treatment Landscape | DelveInsight
STS market growth.Advances in Soft Tissue Sarcoma Biology: Improved understanding of STS biology, including fusion-driven sarcomas, CDK4/MDM2-amplified liposarcoma, and angiogenic signaling, has strengthened the rationale for therapeutic development beyond cytotoxic chemotherapy.Robust
More news about: DelveInsight Business Research, LLP
Jul 13, 2026, 10:31 ET Metastatic Castration-resistant Prostate Cancer Market Poised for Strong Growth by 2036, Due to the Launch of Drug Classes Such as Anti-B7-H3 ADC, PROTAC Protein Degrader, NTD AR Inhibitor, Radionuclide Therapy, and Several Others | DelveInsight
mCRPC CDK12 Alteration Immunotherapy Pembrolizumab Treatment OutcomesRecent Developments in the Metastatic Castration-resistant Prostate Cancer
More news about: DelveInsight Business Research, LLP
Jun 30, 2026, 00:00 ET Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
areas, and Eli Lilly and Company (NYSE: LLY) today jointly announced that they have entered into a distribution and promotion agreement regarding Lilly's CDK4 & 6 inhibitor Verzenios® (abemaciclib) in mainland China: Innovent will be responsible for the importation, marketing,
More news about: Innovent Biologics
Jun 23, 2026, 08:05 ET Silent Partner AI Secures Strategic Growth Investment from NYO Capital
dealerships across North America and integrates with the automotive industry's leading CRM and DMS platforms, including VinSolutions, DealerSocket, CDK, eLead, Tekion, and Reynolds & Reynolds. The company's solutions help dealerships capture missed opportunities, improve lead engagement, automate
More news about: Silent Partner
Jun 11, 2026, 08:11 ET Oncura Health Physicians Recognized for Research Contributions at ASCO 2026
leadership of Dr. Seneviratne, the program has participated in first-in-human clinical research, including early work involving novel mechanisms such as CDK degraders in breast cancer, highlighting the organization's ability to bring cutting-edge therapies into the community setting."Our goal is to
More news about: Oncura Health
Jun 04, 2026, 09:00 ET TrueCar Adds Two New Industry Leaders to Strengthen Partnerships with Automakers and Build out New Insurance Vertical
CDK Global, rising to Vice President of Global Enterprise Solutions, where he oversaw relationships with major OEM clients including
More news about: TrueCar, Inc.
Jun 01, 2026, 06:01 ET A combined therapeutic strategy aims to improve disease control in advanced hormone‑sensitive prostate cancer
monotherapy. The study includes patients with ER+/HER2‑ tumors who developed an ESR1 gene mutation after progression on prior endocrine therapy and CDK4/6 inhibitors. The trial is being implemented in more than 100 hospitals across nine countries, including Spain, Austria, the Czech Republic, Greece,
More news about: MEDSIR
May 30, 2026, 15:25 ET Menarini Group 於 2026 年美國臨床腫瘤學會 (ASCO) 週年大會上發表第 1b/2 期 ELEVATE 研究中，使用埃拉司群 (Elacestrant) 聯合卡帕塞替尼 (Capivasertib) 治療 ER+、HER2- 轉移性乳癌 (mBC) 患者的最新數據。
ELEVATE 研究目的在於評估埃拉司群聯合治療方案的安全性及療效，期望克服 ER+/HER2- 轉移性乳癌中觀察到的不同抗藥性機制，並且在不論 ESR1 突變狀態如何的情況下，提升患者治療成果。 研究包含六種治療方案，分別評估埃拉司群與 CDK4/6 抑制劑（帕博西尼 (palbociclib)、阿貝馬西利 (abemaciclib) 及瑞博西利 (ribociclib)），以及 PI3K/AKT/mTOR 訊號傳導途徑抑制劑（依維莫司 (everolimus)、阿培利西 (alpelisib) 和卡帕塞替尼 (capivasertib)）聯合治療的療效。2026
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 09:09 ET Il Gruppo Menarini presenta nuovi dati dello studio ELEVATE di fase 1b/2 su elacestrant in combinazione con capivasertib in pazienti con carcinoma mammario metastatico (mBC) ER+, HER2- in occasione del Congresso annuale 2026 dell'American Society of Clinical Oncology (ASCO)
indipendentemente dallo stato di mutazione di ESR1. Lo studio prevede sei regimi terapeutici che valutano elacestrant in combinazione con inibitori di CDK4/6 (palbociclib, abemaciclib e ribociclib) e con inibitori della via PI3K/AKT/mTOR (everolimus, alpelisib e capivasertib).I risultati dello studio
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 09:07 ET Menarini Group apresenta novos dados do estudo ELEVATE de Fase 1b/2 sobre o elacestranto em associação com o capivasertibe em pacientes com câncer de mama metastático (CMm) ER+, HER2- no Congresso Anual de 2026 da American Society of Clinical Oncology (ASCO)
independentemente do status da mutação ESR1. O estudo é composto por seis regimes de tratamento que avaliam o elacestranto em combinação com inibidores de CDK4/6 (palbociclibe, abemaciclibe e ribociclibe) e com inibidores da via PI3K/AKT/mTOR (everolimo, alpelisibe e capivasertibe).Resultados do estudo
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 09:02 ET Menarini Group presenta nuevos datos del ensayo ELEVATE de fase 1b/2 de elacestrant combinado con capivasertib en pacientes con cáncer de mama metastásico (CMM) con receptores de estrógeno positivos (ER+) y HER2 negativo (HER2-) en la reunión anual de la Sociedad Estadounidense de Oncología Clínica (ASCO) de 2026
therapy + CDK4/6i*#" (ADELA: Un ensayo de fase 3 aleatorizado, doble ciego y controlado con placebo de elacestrant + everolimus en comparación con elacestrant + placebo en pacientes con cáncer de mama avanzado ER+/HER2- con tumores mutados en ESR1 que progresan con terapia endocrina + CDK4/6i *#)
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 06:52 ET Menarini Group、ASCO2026でER+/HER2-転移性乳がん対象エラセストラント・カピバセルチブ併用ELEVATE試験の新データを発表
分～4時30分（CT）場所：ポスターボード212発表者：Wassim McHayleh氏発表タイトル：ADELA：内分泌療法＋CDK4/6i*#で病勢進行したESR1変異腫瘍を有するER+/HER2-進行乳がん患者を対象とした、エラセストラント＋エベロリムスとエラセストラント＋プラセボを比較する二重盲検プラセボ対照無作為化第3相試験抄録番号：TPS1154発表日時：2026年6月1日、午後1時30分～4時30分（CT）場所：ポスターボード262b発表者：Antonio
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 17:06 ET Die Menarini Group präsentiert auf der Jahrestagung 2026 der American Society of Clinical Oncology (ASCO) neue Daten aus der Phase-1b/2-Studie ELEVATE zu Elacestrant in Kombination mit Capivasertib bei Patientinnen mit ER-positivem, HER2-negativem metastasiertem Brustkrebs (mBC)
Patientinnen zu verbessern, unabhängig vom ESR1-Mutationsstatus. Die Studie umfasst sechs Behandlungsschemata, in denen Elacestrant in Kombination mit CDK4/6-Inhibitoren (Palbociclib, Abemaciclib und Ribociclib) sowie mit Inhibitoren des PI3K/AKT/mTOR-Signalwegs (Everolimus, Alpelisib und Capivasertib)
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 11:40 ET Le Groupe Menarini présente de nouvelles données de l'étude ELEVATE sur l'association de l'élacestrant et du capivasertib
statut mutationnel du gène ESR1. L'étude est composée de six schémas thérapeutiques évaluant l'élacestrant en association avec des inhibiteurs de CDK4/6 (palbociclib, abémaciclib et ribociclib) et avec des inhibiteurs de la voie PI3K/AKT/mTOR (évérolimus, alpelisib et capivasertib).Les résultats
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 10:13 ET 메나리니 그룹, 2026 미국임상종양학회(ASCO) 연례회의에서 ER+, HER2- 전이성 유방암(mBC) 환자를 대상으로 엘라세스트란트와 카피바서팁 병용요법을 평가한 1b/2상 ELEVATE 시험 신규 데이터 발표
ELEVATE 시험은 ER+/HER2- mBC에서 관찰되는 다양한 내성 기전을 극복하고 ESR1 돌연변이 상태와 관계없이 환자 예후를 개선하기 위해 엘라세스트란트 병용 투여 옵션의 안전성과 유효성을 평가하도록 설계됐다. 이 시험은 엘라세스트란트를 CDK4/6 억제제(팔보시클립, 아베마시클립 및 리보시클립), PI3K/AKT/mTOR 경로 억제제(에베로리무스, 알펠리십 및 카피바서팁)와 각각 병용 평가하는 6개 치료 요법으로 구성돼 있다.ASCO 2026에서 보고되는 ELEVATE 결과(초록 1098)[1]에는
More news about: Menarini Industrie Farmaceutiche Riunite